查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018488

犬異位性皮膚炎市場：依治療方法、劑型及通路分類－2026-2032年全球市場預測

Canine Atopic Dermatitis Market by Treatment Type, Form Type, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，犬類異位性皮膚炎市場價值將達到 18.3 億美元，到 2026 年將成長至 19.8 億美元，到 2032 年將達到 33 億美元，複合年成長率為 8.75%。

主要市場統計數據
基準年 2025 18.3億美元
預計年份：2026年 19.8億美元
預測年份 2032 33億美元
複合年成長率 (%) 8.75%

簡明扼要地概述了影響犬異位性皮膚炎現狀的臨床複雜性、未滿足的需求和策略緊迫性，供相關人員參考。

犬異位性皮膚炎是一個複雜的領域，涉及免疫學、慢性病管理和不斷發展的治療方案，需要製造商、臨床醫生和經銷商進行謹慎的策略考量。此疾病的多因素特性導致治療方法迅速多樣化，涵蓋了從生物目標製劑和全身性抗發炎療法到補充營養劑和用於緩解症狀的外用製劑等。隨著相關人員重新評估其優先事項，臨床療效、安全性以及飼主偏好正成為產品開發和臨床應用的關鍵促進因素。

治療方法的創新、監管壓力以及飼主期望的變革性轉變，正在推動犬類皮膚病治療途徑的重新定義。

犬異位性皮膚炎的治療格局正經歷著一場變革，其驅動力包括科學進步、飼主不斷變化的需求以及整個供應鏈的運作壓力。分子生物學和免疫學的突破性進展使生物製藥，尤其是單株抗體，從實驗性療法轉變為能夠有效緩解症狀且安全性良好的實用治療方法。同時，飼主越來越需要整合處方藥、營養補充劑和差異化外用護理的綜合治療方案，這為涵蓋臨床和健康管理兩方面的混合產品策略創造了空間。

評估美國於 2025 年宣布的關稅措施對獸醫皮膚病學原料和價格趨勢的累積營運和供應鏈影響。

美國2025年宣布的關稅措施對採購皮膚科治療原料、成品和特殊成分的公司提出了重大考量。在整個價值鏈中，進口關稅的增加以及相關的行政成本上升，推高了某些活性成分、添加劑和包裝材料的接收成本。這促使企業重新評估庫存策略，許多公司增加了關鍵原料的安全庫存，並重新評估前置作業時間，以降低海關相關風險。

以細分市場主導的洞察，揭示了治療類型、產品形式、分銷管道和處方途徑如何相互交織，並指南商業化策略。

一套精細的市場區隔框架揭示了臨床和商業性層面的機會和限制因素。從治療類型來看，市場涵蓋生物製藥（其中單株抗體是主要的創新載體）、營養保健品（以膳食補充劑為例）、注射劑或口服片劑等全身性治療藥物，以及乳膏、凝膠、洗髮精和噴霧等外用藥物。治療類型的多樣性要求每種治療類別都應有不同的監管路徑、研發進度和臨床醫生教育策略。

北美、歐洲、中東和非洲以及亞太地區的區域趨勢和跨境因素正在重塑犬類藥物的​​取得和報銷方式。

區域趨勢對治療的可近性、定價以及治療方法的普及率有著決定性的影響。在美洲，成熟的獸醫網路和不斷成長的寵物醫療保健支出推動了對差異化治療方法的強勁需求，而監管機構則強調基於證據的核准和清晰的安全性數據。在該地區運營的製造商通常優先考慮與專科診所建立合作關係以及採用整合的分銷模式，以確保獲得臨床醫生的支持並支持上市後的監測活動。

犬異位性皮膚炎治療生態系中成功企業的關鍵企業行為、競爭優勢與合作模式。

成功的公司透過結合專注的研發投入、靈活的生產策略和差異化的商業化模式來脫穎而出。主要企業正將資源投入到標靶生物製劑平台，以推進具有明確安全性和有效性的單株抗體候選藥物的研發，同時開發補充營養品系列，以增強治療的連續性並擴展整體治療方案。這種整合的產品組合能夠分階段交付產品，從而滿足臨床需求和飼主的偏好。

為產業領導者提供切實可行的建議，提出優先的戰術性和策略步驟，以加速採用、最佳化供應鏈和增強市場進入。

產業領導者應採取多管齊下的策略，兼顧短期商業化成果及中期平台建置。優先進行治療方法，重點關注對臨床醫生和患者至關重要的終點指標，例如減輕持續性搔癢、真實臨床環境下的安全性以及改善生活品質指標。投資可操作的臨床試驗和完善的核准後監測，有助於增強臨床醫師的信心，並支持擴大適應症範圍。

透明的調查方法，詳細說明了混合方法、數據檢驗過程以及支撐分析和建議的局限性。

本執行摘要的分析採用了一種混合方法，結合了定性訪談、結構化二手研究以及跨多個資料流的檢驗，以確保獲得可靠且可操作的見解。主要資訊來源包括對全科和皮膚科診所的執業獸醫、製造和分銷機構的採購和運營經理以及製藥研發公司的業務拓展負責人的深度訪談。這些訪談提供了關於臨床重點、供應鏈脆弱性和分銷管道經濟效益的第一手觀點。

這個結論概述了相關人員在了解犬類皮膚病學不斷變化的格局時所面臨的策略挑戰、風險因素和未來應對策略。

犬異位性皮膚炎領域瞬息萬變，既帶來了戰略挑戰，也蘊藏著實際機會。標靶治療的進步和實證醫學方法的日益成熟，為臨床差異化治療開闢了新的途徑；同時，飼主行為和分銷模式的改變也拓展了市場准入管道。此外，關稅措施和日益複雜的供應鏈等宏觀趨勢，也要求企業提高營運警覺性，並制定靈活的策略規劃。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：犬異位性皮膚炎市場：依治療方法

  • 生物製藥
  • 營養保健品
  • 全身性治療
    • 注射藥物
    • 口服錠劑
  • 外用製劑
    • 乳霜/凝膠
    • 洗髮精
    • 噴

第9章：犬異位性皮膚炎市場：依劑型分類

  • 乳霜/凝膠
  • 注射藥物
  • 口服錠劑
  • 洗髮精
  • 噴

第10章：犬異位性皮膚炎市場：依分銷管道分類

  • 線上零售
  • 寵物專賣店
  • 藥局
  • 獸醫醫院和診所

第11章：犬異位性皮膚炎市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章：犬異位性皮膚炎市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章：犬異位性皮膚炎市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章：美國：犬異位性皮膚炎市場

第15章 中國：犬異位性皮膚炎市場

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Animal Dermatology Group, Inc.
  • Aratana Therapeutics, Inc.
  • Aventix Animal Health
  • Bayer AG
  • Bimeda Inc.
  • BioCeltix Corporation
  • Bioiberica SAU
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale SA
  • Dechra Pharmaceuticals plc
  • Elanco Animal Health Incorporated
  • Hill's Pet Nutrition, Inc.
  • Huvepharma EOOD
  • LEO Pharma A/S
  • Merck Sharp & Dohme Corp.
  • Nextmune AB
  • Novartis AG
  • OKAVA Pharmaceuticals, Inc.
  • PetIQ, Inc.
  • Pilgrim Animal Health
  • Royal Canin SAS
  • Vetoquinol SA
  • Virbac SA
  • Zoetis Inc.
Product Code: MRR-A339DAEFA20E

The Canine Atopic Dermatitis Market was valued at USD 1.83 billion in 2025 and is projected to grow to USD 1.98 billion in 2026, with a CAGR of 8.75%, reaching USD 3.30 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.83 billion
Estimated Year [2026] USD 1.98 billion
Forecast Year [2032] USD 3.30 billion
CAGR (%) 8.75%

A concise introduction outlining the clinical complexity, unmet needs, and strategic urgency shaping the canine atopic dermatitis landscape for stakeholders

Canine atopic dermatitis presents a complex intersection of immunology, chronic care management, and evolving treatment options that demand careful strategic consideration from manufacturers, clinicians, and distributors. The condition's multifactorial nature has driven rapid diversification of therapeutic approaches, spanning targeted biological agents, systemic anti-inflammatory regimens, adjunctive nutraceuticals, and symptom-relief topical formulations. As stakeholders reassess priorities, clinical efficacy, safety profiles, and owner preferences are emerging as the dominant axes shaping commercialization and clinical adoption.

In parallel, the regulatory and reimbursement environment for veterinary therapeutics is becoming more nuanced, with increased scrutiny on clinical evidence and post-market safety monitoring. This shift amplifies the importance of rigorous trial design, real-world evidence collection, and proactive pharmacovigilance. Consequently, companies must coordinate clinical development, manufacturing quality, and go-to-market planning more tightly than in prior cycles. The remainder of this executive summary synthesizes the most consequential trends, presents segmentation and regional insights, examines 2025 tariff implications in the United States, and concludes with prioritized, actionable recommendations for market participants seeking sustained competitive advantage.

Transformative shifts in therapeutic innovation, regulatory pressures, and pet owner expectations driving a redefinition of treatment pathways in canine dermatology

The therapeutic landscape for canine atopic dermatitis is undergoing transformative change driven by scientific advances, shifting pet owner expectations, and operational pressures across supply chains. Breakthroughs in molecular biology and immunology have elevated biologics, particularly monoclonal antibodies, from experimental options to practical therapies that deliver targeted relief with favorable safety profiles. Simultaneously, owners increasingly demand integrated care pathways that combine prescription therapies with nutraceutical support and differentiated topical care, creating space for hybrid product strategies that straddle clinical and wellness categories.

Regulatory evolution and payer behavior are also altering commercial calculus. Regulators are emphasizing robust evidence packages and clearer labeling on off-label human drug adaptations, prompting sponsors to invest earlier in controlled studies and long-term safety monitoring. On the commercial front, omnichannel distribution and telemedicine are reshaping access, allowing specialty clinics and online retailers to coexist with traditional veterinary practices. Technology-enabled adherence tools and digital engagement strategies are enhancing owner compliance and enabling richer real-world datasets to support product differentiation. Together, these shifts are accelerating product lifecycle decisions, elevating the importance of strategic partnerships, and requiring nimble operating models that can respond to both clinical and market-driven imperatives.

Assessing the cumulative operational and supply chain effects of United States tariff measures announced in 2025 on veterinary dermatology inputs and pricing dynamics

Tariff measures announced in the United States in 2025 have introduced a material set of considerations for companies sourcing raw materials, finished goods, and specialized components for dermatologic therapies. Across the value chain, import duties and related administrative costs have increased landed costs for certain active pharmaceutical ingredients, excipients, and packaging supplies. This has led to a recalibration of inventory strategies, with many firms extending safety stocks for critical inputs and re-evaluating lead times to mitigate exposure to customs-related variability.

Procurement teams have responded by accelerating supplier diversification efforts, prioritizing nearshoring and regional suppliers to shorten logistical pathways and reduce tariff dependency. While these efforts can enhance resilience, they also raise questions about supply quality, regulatory alignment, and cost competitiveness. Pricing strategies have faced pressure, as manufacturers weigh partial cost pass-through to veterinary clinics and retail channels against the risk of dampening demand. In parallel, smaller innovators with limited negotiating leverage have explored contract manufacturing partnerships and bundled sourcing agreements to preserve margins.

Clinical development programs have felt secondary effects; increased costs for specialized reagents and international CRO services have prompted tighter protocol efficiency and selective enrollment strategies. Regulatory dossiers have required additional documentation to demonstrate supply chain controls and product consistency when supplier changes occur. Overall, the 2025 tariff landscape has reinforced the need for dynamic sourcing, proactive stakeholder communication, and scenario-based financial planning to protect continuity of supply and maintain affordability for end users.

Segment-driven intelligence revealing how treatment types, product forms, distribution channels, and prescription pathways converge to inform commercialization strategies

A nuanced segmentation framework illuminates opportunities and constraints across both clinical and commercial dimensions. When viewed through the lens of treatment type, the market spans biologics-where monoclonal antibodies represent a focal innovation vector-nutraceuticals typified by supplemental formulations, systemic therapies delivered via injections and oral tablets, and topicals available as creams and gels, shampoos, and sprays. This treatment-type diversity mandates distinct regulatory pathways, development timelines, and clinician education strategies for each therapeutic category.

Product-type segmentation further differentiates market approaches by delineating OTC options from prescription-only therapies, with each pathway shaping marketing compliance, distribution partnerships, and point-of-care conversations. Distribution channel segmentation highlights critical go-to-market choices across online retail, pet specialty stores, traditional pharmacies, and veterinary hospitals and clinics, each offering different margin profiles, channel controls, and data capture opportunities. Finally, form-type considerations-ranging from creams and gels to injections, oral tablets, shampoos, and sprays-affect formulation complexity, stability requirements, and owner adherence dynamics. Taken together, these interlocking segmentation axes demand that manufacturers tailor clinical evidence generation, packaging, and commercialization plans to the specific intersection of treatment type, regulatory status, channel strategy, and product form to maximize adoption and long-term therapeutic success.

Regional dynamics and cross-border considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific that are reshaping access and reimbursement for canine therapies

Regional dynamics exert a decisive influence on access, pricing, and the speed of therapeutic adoption. In the Americas, well-established veterinary care networks and growing pet healthcare spend are driving strong demand for differentiated therapies, while regulatory expectations favor evidence-based approvals and clear safety profiles. Manufacturers operating in this region often prioritize partnerships with specialty clinics and integrated distribution models to ensure clinician buy-in and to support post-launch surveillance initiatives.

The Europe, Middle East & Africa region presents a heterogeneous regulatory and reimbursement environment where country-level variations in veterinary regulation and import rules require flexible market entry strategies. Here, clinical data that aligns with local regulatory standards and careful navigation of cross-border logistics are essential. Manufacturers can benefit from regional distribution partnerships and localized manufacturing arrangements to address tariff and compliance challenges.

Across Asia-Pacific, rapid pet ownership growth and expanding veterinary services are creating opportunities for accelerated uptake, particularly in urban centers where awareness and willingness to invest in premium therapies are higher. However, market entry must consider diverse regulatory frameworks, variable cold-chain infrastructure for certain biologics, and localized preferences for nutraceutical and topical solutions. In all regions, aligning clinical messaging to local veterinary practice patterns and owner expectations, while adapting supply chain and pricing strategies to regional constraints, will determine commercial success.

Key corporate behaviors, competitive differentiation, and collaboration models that define successful players in the canine atopic dermatitis therapeutic ecosystem

Successful firms are distinguishing themselves through a combination of focused R&D investment, flexible manufacturing strategies, and differentiated commercialization models. Leading companies are channeling resources into targeted biologic platforms, advancing monoclonal antibody candidates with clear safety and efficacy narratives, while simultaneously developing supportive nutraceutical lines that enhance adherence and broaden total addressable therapy bundles. These integrated portfolios enable a tiered offering that meets both clinical needs and owner preferences.

Strategic partnerships are common, with firms forming alliances across clinical research organizations, contract manufacturers, and distribution specialists to compress development timelines and secure capacity. Companies prioritizing omnichannel distribution, including digital-first engagement tools and telehealth-enabled diagnostic support, are improving owner education and adherence tracking. Additionally, innovators are investing in post-market evidence collection to substantiate long-term safety claims and to support label expansions. Operational excellence is also emerging as a competitive advantage: those that optimize supply chain redundancy, establish regional manufacturing nodes, and maintain transparent quality systems reduce time-to-supply disruptions and reinforce trust with veterinary professionals. Ultimately, corporate success hinges on aligning scientific differentiation with pragmatic commercialization execution and resilient operations.

Actionable recommendations offering prioritized tactical and strategic moves for industry leaders to accelerate adoption, optimize supply chains, and strengthen market access

Industry leaders should adopt a multi-pronged strategy that balances near-term commercialization wins with medium-term platform building. First, prioritize clinical evidence generation for differentiated therapies, focusing on endpoints that matter to clinicians and owners such as sustained pruritus reduction, safety in real-world settings, and improvement in quality-of-life metrics. Investing in pragmatic trials and robust post-approval surveillance will accelerate clinician confidence and support label-strengthening opportunities.

Second, diversify sourcing and adapt supply chain architecture to mitigate tariff and logistics volatility. Establishing regional supplier relationships, qualifying multiple contract manufacturers, and improving demand forecasting through closer collaboration with distribution partners will reduce vulnerability to tariff-induced cost shocks. Third, pursue omnichannel go-to-market models that combine veterinary clinic education, digital engagement for owners, and selective retail partnerships. Tailor messaging to the product's regulatory status-OTC communications should emphasize safe, everyday use while prescription campaigns must center on clinical efficacy and veterinarian guidance.

Fourth, leverage strategic alliances to access complementary capabilities, including assay development, adherence technologies, and localized regulatory support. Finally, align pricing strategies with demonstrated value while preparing tactical rebates or value-based contracting pilots with large veterinary networks. Collectively, these actions will strengthen market access pathways, improve resilience against macro disruptions, and create durable differentiation in a competitive landscape.

Transparent research methodology detailing the mixed-methods approach, data validation processes, and limitations underpinning the analysis and recommendations

The analysis underpinning this executive summary employed a mixed-methods approach combining primary qualitative interviews, structured secondary research, and triangulation across multiple data streams to ensure robust, actionable insights. Primary inputs included in-depth interviews with practicing veterinarians across general practice and dermatology specialty clinics, procurement and operations leaders within manufacturing and distribution organizations, and business development executives from therapeutic innovators. These interviews provided first-line perspectives on clinical priorities, supply chain vulnerabilities, and channel economics.

Secondary research encompassed peer-reviewed literature on canine dermatologic pathophysiology and treatment efficacy, regulatory guidance documents, and publicly available corporate filings and clinical trial registries. Data points from different sources were cross-validated to identify consistent themes and to reconcile divergent findings. Methodological rigor was further enhanced by scenario modeling to test the sensitivity of operational and pricing outcomes to tariff-related disruptions and supply chain delays. Limitations include the inherent variability in regional regulatory regimes and the evolving evidence base for newer therapeutic classes; where uncertainties existed, the analysis emphasized risk-adjusted recommendations and transparency about assumptions to support informed decision-making.

Concluding synthesis that distills strategic imperatives, risk considerations, and next steps for stakeholders navigating the evolving canine dermatology landscape

The evolving canine atopic dermatitis environment presents both strategic challenges and tangible opportunities. Advances in targeted therapies and a maturing evidence base are creating new pathways for clinical differentiation, while shifts in owner behavior and distribution models are expanding routes to market. At the same time, macro-level dynamics such as tariff actions and supply chain complexity necessitate heightened operational vigilance and flexible strategic planning.

Stakeholders that integrate rigorous clinical development with resilient supply chain design and omnichannel commercialization will be best positioned to capture emerging value. Key imperatives include generating clinically relevant evidence, investing in diversified sourcing and manufacturing, and aligning pricing and access strategies with demonstrated therapeutic value. By prioritizing these areas and following the actionable recommendations outlined, organizations can navigate current headwinds and establish a durable foundation for growth and therapeutic leadership in canine dermatology.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Canine Atopic Dermatitis Market, by Treatment Type

  • 8.1. Biologics
  • 8.2. Nutraceuticals
  • 8.3. Systemic Therapies
    • 8.3.1. Injections
    • 8.3.2. Oral Tablets
  • 8.4. Topicals
    • 8.4.1. Creams & Gels
    • 8.4.2. Shampoo
    • 8.4.3. Sprays

9. Canine Atopic Dermatitis Market, by Form Type

  • 9.1. Creams & Gels
  • 9.2. Injections
  • 9.3. Oral Tablets
  • 9.4. Shampoo
  • 9.5. Sprays

10. Canine Atopic Dermatitis Market, by Distribution Channel

  • 10.1. Online Retail
  • 10.2. Pet Specialty Stores
  • 10.3. Pharmacies
  • 10.4. Veterinary Hospitals Clinics

11. Canine Atopic Dermatitis Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Canine Atopic Dermatitis Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Canine Atopic Dermatitis Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Canine Atopic Dermatitis Market

15. China Canine Atopic Dermatitis Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. AbbVie Inc.
  • 16.6. Animal Dermatology Group, Inc.
  • 16.7. Aratana Therapeutics, Inc.
  • 16.8. Aventix Animal Health
  • 16.9. Bayer AG
  • 16.10. Bimeda Inc.
  • 16.11. BioCeltix Corporation
  • 16.12. Bioiberica S.A.U.
  • 16.13. Boehringer Ingelheim International GmbH
  • 16.14. Ceva Sante Animale S.A.
  • 16.15. Dechra Pharmaceuticals plc
  • 16.16. Elanco Animal Health Incorporated
  • 16.17. Hill's Pet Nutrition, Inc.
  • 16.18. Huvepharma EOOD
  • 16.19. LEO Pharma A/S
  • 16.20. Merck Sharp & Dohme Corp.
  • 16.21. Nextmune AB
  • 16.22. Novartis AG
  • 16.23. OKAVA Pharmaceuticals, Inc.
  • 16.24. PetIQ, Inc.
  • 16.25. Pilgrim Animal Health
  • 16.26. Royal Canin S.A.S.
  • 16.27. Vetoquinol S.A.
  • 16.28. Virbac S.A.
  • 16.29. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANINE ATOPIC DERMATITIS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CANINE ATOPIC DERMATITIS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES CANINE ATOPIC DERMATITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA CANINE ATOPIC DERMATITIS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY NUTRACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY NUTRACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY NUTRACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY INJECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY INJECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY INJECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY ORAL TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY ORAL TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY ORAL TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY CREAMS & GELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY CREAMS & GELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY CREAMS & GELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SHAMPOO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SHAMPOO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SHAMPOO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SPRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SPRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SPRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY CREAMS & GELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY CREAMS & GELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY CREAMS & GELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY INJECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY INJECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY INJECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY ORAL TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY ORAL TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY ORAL TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SHAMPOO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SHAMPOO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SHAMPOO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SPRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SPRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SPRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY ONLINE RETAIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY ONLINE RETAIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY PET SPECIALTY STORES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY PET SPECIALTY STORES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY PET SPECIALTY STORES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY VETERINARY HOSPITALS CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY VETERINARY HOSPITALS CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY VETERINARY HOSPITALS CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS CANINE ATOPIC DERMATITIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. GCC CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GCC CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. GCC CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 120. GCC CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 121. GCC CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. GCC CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. G7 CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. G7 CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. G7 CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 138. G7 CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 139. G7 CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. G7 CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. NATO CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. NATO CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. NATO CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 144. NATO CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 145. NATO CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. NATO CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. UNITED STATES CANINE ATOPIC DERMATITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. UNITED STATES CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. UNITED STATES CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED STATES CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED STATES CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED STATES CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. CHINA CANINE ATOPIC DERMATITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. CHINA CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. CHINA CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 157. CHINA CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 158. CHINA CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. CHINA CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)